Floatz logo

Busulphan

Glanzmann Thrombasthenia

Masonic Cancer Center, University of MinnesotaN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Glanzmann Thrombasthenia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2CCC
Fludarabine
Roswell Park Cancer Institute
Phase 2CCC
Coagulation Factor Viia Variant
Catalyst Biosciences
Phase 1/2CCC
ABATACEPT RECOMBINANT
Emory University
Phase 1CC
Alefacept
Emory University
N/AD
Anti-Thymoglobulin, Rabbit
Masonic Cancer Center, University of Minnesota
N/AD

Same molecule, other indications

Busulphan is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
76 / 100
View asset →
graft versus host diseaseDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →